183 related articles for article (PubMed ID: 33115415)
1. Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.
Ebert K; Zwingenberger G; Barbaria E; Keller S; Heck C; Arnold R; Hollerieth V; Mattes J; Geffers R; Raimúndez E; Hasenauer J; Luber B
BMC Cancer; 2020 Oct; 20(1):1039. PubMed ID: 33115415
[TBL] [Abstract][Full Text] [Related]
2. Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF.
Ebert K; Haffner I; Zwingenberger G; Keller S; Raimúndez E; Geffers R; Wirtz R; Barbaria E; Hollerieth V; Arnold R; Walch A; Hasenauer J; Maier D; Lordick F; Luber B
BMC Cancer; 2022 Mar; 22(1):254. PubMed ID: 35264144
[TBL] [Abstract][Full Text] [Related]
3. Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.
Keller S; Zwingenberger G; Ebert K; Hasenauer J; Wasmuth J; Maier D; Haffner I; Schierle K; Weirich G; Luber B
Mol Oncol; 2018 Apr; 12(4):441-462. PubMed ID: 29325228
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Afatinib and Lapatinib Against
Nakata S; Fujita M; Nakanishi H
Anticancer Res; 2019 Nov; 39(11):5927-5932. PubMed ID: 31704817
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of epidermal growth factor receptor signaling effects in gastric cancer cell lines by detailed motility-focused phenotypic characterization linked with molecular analysis.
Keller S; Kneissl J; Grabher-Meier V; Heindl S; Hasenauer J; Maier D; Mattes J; Winter P; Luber B
BMC Cancer; 2017 Dec; 17(1):845. PubMed ID: 29237412
[TBL] [Abstract][Full Text] [Related]
6. MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells.
Ebert K; Mattes J; Kunzke T; Zwingenberger G; Luber B
PLoS One; 2019; 14(9):e0223225. PubMed ID: 31557260
[TBL] [Abstract][Full Text] [Related]
7.
Sanchez-Vega F; Hechtman JF; Castel P; Ku GY; Tuvy Y; Won H; Fong CJ; Bouvier N; Nanjangud GJ; Soong J; Vakiani E; Schattner M; Kelsen DP; Lefkowitz RA; Brown K; Lacouture ME; Capanu M; Mattar M; Qeriqi B; Cecchi F; Tian Y; Hembrough T; Nagy RJ; Lanman RB; Larson SM; Pandit-Taskar N; Schöder H; Iacobuzio-Donahue CA; Ilson DH; Weber WA; Berger MF; de Stanchina E; Taylor BS; Lewis JS; Solit DB; Carrasquillo JA; Scaltriti M; Schultz N; Janjigian YY
Cancer Discov; 2019 Feb; 9(2):199-209. PubMed ID: 30463996
[TBL] [Abstract][Full Text] [Related]
8. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
Janjigian YY; Viola-Villegas N; Holland JP; Divilov V; Carlin SD; Gomes-DaGama EM; Chiosis G; Carbonetti G; de Stanchina E; Lewis JS
J Nucl Med; 2013 Jun; 54(6):936-43. PubMed ID: 23578997
[TBL] [Abstract][Full Text] [Related]
9. The combinational therapy of trastuzumab and cetuximab inhibits tumor growth in a patient-derived tumor xenograft model of gastric cancer.
Wang CJ; Tong PJ; Zhu MY
Clin Transl Oncol; 2016 May; 18(5):507-14. PubMed ID: 26370419
[TBL] [Abstract][Full Text] [Related]
10. Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling.
Zheng L; Tan W; Zhang J; Yuan D; Yang J; Liu H
Cancer Immunol Immunother; 2014 Jun; 63(6):581-6. PubMed ID: 24668364
[TBL] [Abstract][Full Text] [Related]
11. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
12. Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.
Kneissl J; Hartmann A; Pfarr N; Erlmeier F; Lorber T; Keller S; Zwingenberger G; Weichert W; Luber B
J Cancer Res Clin Oncol; 2017 Apr; 143(4):573-600. PubMed ID: 27933395
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence.
Yamade M; Sugimoto M; Nishino M; Uotani T; Sahara S; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Miyajima H; Furuta T
Anticancer Res; 2012 Jan; 32(1):105-14. PubMed ID: 22213294
[TBL] [Abstract][Full Text] [Related]
14. Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance.
Zuo Q; Liu J; Zhang J; Wu M; Guo L; Liao W
Sci Rep; 2015 Jun; 5():11634. PubMed ID: 26108989
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.
Martin N; Isambert N; Gomez-Roca C; Goeldner RG; Zanetta S; Sadrolhefazi B; de Mont-Serrat H; Campone M; Delord JP
Cancer Chemother Pharmacol; 2018 Dec; 82(6):979-986. PubMed ID: 30350178
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
18. An unconventional KITENIN/ErbB4-mediated downstream signal of EGF upregulates c-Jun and the invasiveness of colorectal cancer cells.
Bae JA; Yoon S; Park SY; Lee JH; Hwang JE; Kim H; Seo YW; Cha YJ; Hong SP; Kim H; Chung IJ; Kim KK
Clin Cancer Res; 2014 Aug; 20(15):4115-28. PubMed ID: 24893630
[TBL] [Abstract][Full Text] [Related]
19. Identification of different gene expressions between diffuse- and intestinal-type spheroid-forming gastric cancer cells.
Lee JW; Sung JS; Park YS; Chung S; Kim YH
Gastric Cancer; 2019 Sep; 22(5):967-979. PubMed ID: 30726523
[TBL] [Abstract][Full Text] [Related]
20. In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells.
Luca T; Barresi V; Privitera G; Musso N; Caruso M; Condorelli DF; Castorina S
Cell Prolif; 2014 Oct; 47(5):435-47. PubMed ID: 25131935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]